Human medicines European public assessment report (EPAR): Vyepti, eptinezumab, Date of authorisation: 24/01/2022, Revision: 10, Status: Authorised
Vyepti (Eptinezumab) for Migraine Prevention: An Evidence Summary What is established Vyepti is a medicine authorised in the European Union since January 2022 for the preventive treatment of migraine in adults who experience at least 4 migraine days per month. The active ingredient, eptinezumab, is a monoclonal antibody designed to block calcitonin…
Human medicines European public assessment report (EPAR): mResvia, respiratory syncytial virus mRNA vaccine, Date of authorisation: 22/08/2024, Revision: 13, Status: Authorised
What is established On August 22, 2024, the European Medicines Agency (EMA) authorised mResvia, a messenger RNA (mRNA) vaccine designed to prevent respiratory syncytial virus (RSV) infections. RSV is a common cause of respiratory tract infections, particularly in young children and older adults, and can lead to severe illness in vulnerable populations.…
Human medicines European public assessment report (EPAR): Leflunomide ratiopharm, leflunomide, Date of authorisation: 28/11/2010, Revision: 22, Status: Authorised
Evidence Dossier: Leflunomide ratiopharm – European Medicines Agency Assessment What is established Leflunomide ratiopharm is a generic pharmaceutical medicine authorized for use within the European Union, containing the active substance leflunomide. It is used under prescription, primarily for the treatment of adults with active rheumatoid arthritis and active psoriatic arthritis, both autoimmune…
Human medicines European public assessment report (EPAR): Kisunla, donanemab, Date of authorisation: 24/09/2025, Revision: 3, Status: Authorised
What is established Kisunla, containing the active substance donanemab, is an approved medicine in the European Union for treating adults with mild cognitive impairment or mild dementia due to early Alzheimer’s disease. It is authorized specifically for patients with none or only one copy of the apolipoprotein E4 (ApoE4) gene and who…
European SARS-CoV-2 and influenza virus Bioinformatics External Quality Assessment (ESIB-EQA), 2025
European SARS-CoV-2 and Influenza Virus Bioinformatics External Quality Assessment (ESIB-EQA), 2025 This article examines the 2025 report from the European Centre for Disease Prevention and Control (ECDC) on the European SARS-CoV-2 and influenza virus Bioinformatics External Quality Assessment (ESIB-EQA). The assessment evaluates the bioinformatics capabilities of European laboratories in analyzing viral genomic…
ABC's Dr. Tara Narula on Health Misinformation and Where to Turn
Health Misinformation and Trusted Medical Information: Insights from ABC’s Dr. Tara Narula This evidence dossier examines health misinformation issues discussed by Dr. Tara Narula, ABC News’ chief medical correspondent, in the podcast episode of “The Future of Medicine.” The episode aired in November 2026 and focuses on challenges around health misinformation, trust…
Analysis of antimicrobial resistance in the LAKANA trial of azithromycin administration in Mali: A sub-study of a cluster randomized clinical trial
Evidence Dossier: Azithromycin Mass Administration and Antimicrobial Resistance from the LAKANA Trial in Mali What is established Mass drug administration (MDA) of azithromycin has been trialed as a public health intervention to reduce under-five mortality in sub-Saharan Africa, with some studies showing mortality benefit especially when given to children aged 1 to…
With the new shift in the U.S. Congress, time is running out on bills targeting drug patents
What is established A set of bipartisan bills aimed at reforming drug patent laws in the United States is facing a critical deadline before the new Congress convenes in January 2027. These bills seek to address strategies used by pharmaceutical companies to extend monopolies on drugs beyond their original patent terms, thereby…
Human medicines European public assessment report (EPAR): Zybrivo, sintilimab, Status: Opinion
What is established Zybrivo (sintilimab) is a new medicine evaluated by the European Medicines Agency (EMA) for human use. It is an immune checkpoint inhibitor designed to target programmed death-1 (PD-1) receptors, which play a role in regulating immune responses. Such medicines are primarily used in oncology to enhance the body’s immune…
Human medicines European public assessment report (EPAR): Ruxolitinib Krka, ruxolitinib, Status: Opinion
Health & Science Evidence Dossier: Ruxolitinib Krka What is established Ruxolitinib is a protein kinase inhibitor targeting Janus-associated kinases (JAKs), enzymes involved in signaling pathways important for blood cell production and immune regulation. The original branded version, Jakavi, has been authorized in the European Union since 2012 for several conditions, including myelofibrosis,…